BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 9119749)

  • 1. Histocompatibility leukocyte antigen-A2402-restricted cytotoxic T lymphocytes recognizing adenocarcinoma in tumor-infiltrating lymphocytes of patients with colon cancer.
    Gohara R; Nakao M; Ogata Y; Isomoto H; Oizumi K; Itoh K
    Jpn J Cancer Res; 1997 Feb; 88(2):198-204. PubMed ID: 9119749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA class-I-restricted and tumor-specific CTL in tumor-infiltrating lymphocytes of patients with gastric cancer.
    Hoshino T; Seki N; Kikuchi M; Kuramoto T; Iwamoto O; Kodama I; Koufuji K; Takeda J; Itoh K
    Int J Cancer; 1997 Mar; 70(6):631-8. PubMed ID: 9096641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating lymphocytes of patients with non-small cell lung cancer.
    Seki N; Hoshino T; Kikuchi M; Hayashi A; Itoh K
    Cell Immunol; 1997 Feb; 175(2):101-10. PubMed ID: 9023415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HLA-A2402-restricted and tumor-specific cytotoxic T lymphocytes from tumor-infiltrating lymphocytes of a child with Wilms' tumor.
    Nagai K; Yamada A; Eguchi H; Kato H; Itoh K
    Pediatr Res; 1997 Jul; 42(1):122-7. PubMed ID: 9212047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A HER2/NEU-derived peptide, a K(d)-restricted murine tumor rejection antigen, induces HER2-specific HLA-A2402-restricted CD8(+) cytotoxic T lymphocytes.
    Ikuta Y; Okugawa T; Furugen R; Nagata Y; Takahashi Y; Wang L; Ikeda H; Watanabe M; Imai S; Shiku H
    Int J Cancer; 2000 Aug; 87(4):553-8. PubMed ID: 10918197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro induction of HLA-A2402-restricted and carcinoembryonic-antigen-specific cytotoxic T lymphocytes on fixed autologous peripheral blood cells.
    Kim C; Matsumura M; Saijo K; Ohno T
    Cancer Immunol Immunother; 1998 Oct; 47(2):90-6. PubMed ID: 9769117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HLA class I-restricted and tumor-specific cytotoxic T lymphocytes from metastatic lymph nodes of esophageal cancers.
    Toh U; Yamana H; Nakao M; Imai Y; Seki N; Takasu H; Kaneshige T; Fujita H; Shirouzu K; Itoh K
    Cell Immunol; 1997 May; 177(2):137-43. PubMed ID: 9178640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histocompatibility leukocyte antigen-A2-restricted and tumor-specific cytotoxic T lymphocytes from tumor-infiltrating lymphocytes of patient with testicular embryonal cancer.
    Suekane S; Nakao M; Inoue M; Noda S; Itoh K
    Jpn J Cancer Res; 1997 Dec; 88(12):1181-9. PubMed ID: 9473736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene and peptide analyses of newly defined lung cancer antigens recognized by HLA-A2402-restricted tumor-specific cytotoxic T lymphocytes.
    Yamada A; Kawano K; Koga M; Takamori S; Nakagawa M; Itoh K
    Cancer Res; 2003 Jun; 63(11):2829-35. PubMed ID: 12782588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of cellularly processed HLA-A2402-restricted novel CTL epitopes derived from two cancer germ line genes, MAGE-A4 and SAGE.
    Miyahara Y; Naota H; Wang L; Hiasa A; Goto M; Watanabe M; Kitano S; Okumura S; Takemitsu T; Yuta A; Majima Y; Lemonnier FA; Boon T; Shiku H
    Clin Cancer Res; 2005 Aug; 11(15):5581-9. PubMed ID: 16061876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel human HER2-derived peptide homologous to the mouse K(d)-restricted tumor rejection antigen can induce HLA-A24-restricted cytotoxic T lymphocytes in ovarian cancer patients and healthy individuals.
    Okugawa T; Ikuta Y; Takahashi Y; Obata H; Tanida K; Watanabe M; Imai S; Furugen R; Nagata Y; Toyoda N; Shiku H
    Eur J Immunol; 2000 Nov; 30(11):3338-46. PubMed ID: 11093150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The induction of cytotoxic T lymphocytes against HLA-A locus-matched lung adenocarcinoma in patients with non-small cell lung cancer.
    Yoshino I; Takenoyama M; Fujie H; Hanagiri T; Yoshimatsu T; Imabayashi S; Eifuku R; Ogami A; Yano K; Osaki T; Nakanishi R; Ichiyoshi Y; Nomoto K; Yasumoto K
    Jpn J Cancer Res; 1997 Aug; 88(8):743-9. PubMed ID: 9330606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autologous tumor-specific cytotoxic T lymphocytes in a patient with lung adenocarcinoma: implications of the shared antigens expressed in HLA-A24 lung cancer cells.
    Takenoyama M; Yoshino I; Fujie H; Hanagiri T; Yoshimatsu T; Imabayashi S; Eifuku R; Nomoto K; Yasumoto K
    Jpn J Cancer Res; 1998 Jan; 89(1):60-6. PubMed ID: 9510477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for cytotoxic T lymphocyte response against human lung cancer: reconstitution of antigenic epitope with peptide eluted from lung adenocarcinoma MHC class I.
    Calhoun RF; Naziruddin B; Enriquez-Rincon F; Duffy BF; Ritter JM; Sundaresan S; Patterson GA; Cooper JD; Mohanakumar T
    Surgery; 2000 Jul; 128(1):76-85. PubMed ID: 10876189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multidrug resistance-associated protein 3 is a tumor rejection antigen recognized by HLA-A2402-restricted cytotoxic T lymphocytes.
    Yamada A; Kawano K; Koga M; Matsumoto T; Itoh K
    Cancer Res; 2001 Sep; 61(17):6459-66. PubMed ID: 11522641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two proliferation-related proteins, TYMS and PGK1, could be new cytotoxic T lymphocyte-directed tumor-associated antigens of HLA-A2+ colon cancer.
    Shichijo S; Azuma K; Komatsu N; Ito M; Maeda Y; Ishihara Y; Itoh K
    Clin Cancer Res; 2004 Sep; 10(17):5828-36. PubMed ID: 15355913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer.
    Groeper C; Gambazzi F; Zajac P; Bubendorf L; Adamina M; Rosenthal R; Zerkowski HR; Heberer M; Spagnoli GC
    Int J Cancer; 2007 Jan; 120(2):337-43. PubMed ID: 17066423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of HLA class I restriction and the directed antigens of cytotoxic T lymphocytes at the tumor sites of ovarian cancer.
    Yamada A; Kawano K; Harashima N; Niiya F; Nagai K; Kobayashi T; Mine T; Ushijima K; Nishida T; Itoh K
    Cancer Immunol Immunother; 1999; 48(2-3):147-52. PubMed ID: 10414469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of cytotoxic T lymphocytes recognizing autologous tumor cells with plural HLA-class I alleles in a patient with esophageal cancer.
    Maeda T
    Kurume Med J; 1997; 44(1):23-32. PubMed ID: 9154759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of cyclophilin B-derived peptides capable of inducing histocompatibility leukocyte antigen-A2-restricted and tumor-specific cytotoxic T lymphocytes.
    Tamura M; Nishizaka S; Maeda Y; Ito M; Harashima N; Harada M; Shichijo S; Itoh K
    Jpn J Cancer Res; 2001 Jul; 92(7):762-7. PubMed ID: 11473727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.